| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Food Science, Division of Nutritional Sciences [M. E. F., K. A. P., J. A. M.], and Department of Pathobiology [A. M. W., M. A. W.], University of Illinois, Urbana, Illinois 61801
Four different canine mammary tumor (CMT) cell lines and a nonneoplastic primary culture of mammary cells were examined for their in vitro responsiveness to selenium supplementation. These cell lines were found to vary in their metabolic response to increasing concentrations of selenium. Sensitivity to selenium, as sodium selenite, increased with increasing concentrations of this trace element in all of the neoplastic lines. These data also suggest that increasing the plating density of tumor cells further increases the sensitivity to selenium. A relatively seleniumsensitive cell line (CMT-13) and relatively insensitive cell line (CMT-11) were characterized on the basis of reduced growth resulting from selenium supplementation. Increasing the concentration of selenium to 0.75 µg/ml depressed the growth of CMT-13 and CMT-11 cells by 75% and 11%, respectively, while no inhibition was observed in nonneoplastic cells. These cell lines also varied in their sensitivity to different forms of selenium. Selenodiglutathione was the most effective form of selenium examined that inhibited tumor cell growth. The sensitivity of the neoplastic lines was selenodiglutathione » sodium selenite » selenocystine > selenomethionine. None of the forms of selenium examined inhibited the growth of the nonneoplastic mammary cells in culture. Supplementation with sodium selenite (1 µg Se per ml) for 60 min resulted in a dramatic depression in RNA biosynthesis in CMT-13, but not CMT-11 or nonneoplastic cells.
1 Supported in part by USPHS Grant 5T32 CA 090607 and United States Department of Agriculture, Science, and Education Administration Grant 5901-0410-9-0243; American Cancer Society, Illinois Division, Inc., Grant 82-2; and USPHS Grant CA33699 awarded by the National Cancer Institute, Department of Health and Human Services. Presented in part at the Third International Symposium on Selenium in Biology and Medicine, Beijing, China (42).
2 Present address: University of Medicine and Dentistry of New Jersey, School of Osteopathic Medicine, Medical Arts Building, 300 Broadway, Camden, NJ 08103.
Received 1/22/85. Revised 2/24/86. Accepted 3/28/86.
This article has been cited by other articles:
![]() |
S. Cao, F. A. Durrani, and Y. M. Rustum Selective Modulation of the Therapeutic Efficacy of Anticancer Drugs by Selenium Containing Compounds against Human Tumor Xenografts Clin. Cancer Res., April 1, 2004; 10(7): 2561 - 2569. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |